Short answer
Maze Therapeutics, Inc. (MAZE) filed an 8-K current report with the SEC on May 22, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers). Senior Vice President of Finance Amy Bachrodt resigning effective June 1, 2026.
Maze Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.02 · Departure/Election of Directors or Officers
- Senior Vice President of Finance Amy Bachrodt resigning effective June 1, 2026
- Departure unrelated to disagreements over operations, policies, practices, or financial reporting
- CFO Misbah Tahir assuming principal accounting officer responsibilities
- Combined CFO and principal accounting officer roles increase finance leadership concentration
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Maze Therapeutics, Inc. 8-K filings
Get the next MAZE 8-K as it lands
Follow MAZE for push alerts, or ask the research agent what this filing means.